Comparative Study
Journal Article
Add like
Add dislike
Add to saved papers

Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.

AIM: To test the prognostic significant of clinicopathologic factors in patients affected by well-differentiated thyroid carcinoma (WDTC).

METHODS: A retrospective review of patients treated for WDTC (thyroidectomy and a radioactive iodine (1131) thyroid ablation) at our Institute with a minimum of 10 years of follow-up was carried out. The unfavourable prognosis at the end of the follow-up was defined as persistence/recurrence of WDTC or death due to the cancer.

RESULTS: 234 patients (162 female, 72 male), mean age of 47.6 +/- 166 years, were included in this study (mean follow-up 158.4 +/- 34.8 months): 78 (33.4%) subjects had persistence/recurrence of neoplasia while 5 (2.1%) died for cancer. The multivariate regression showed that prognostic factors were old age, size of cancer, detectable thyroglonulin levels six months after metabolic ablation, and DeGroot staging system.

DISCUSSION: Our mortality rate is lower (2.1%) than reported in literature (10%): this could be explained by the different pathological classification and treatment. The mortality rate appears higher in patients treated with emitiroidectomy and TSH suppressive therapy than in those with total thyroidectomy and I131 ablation. Even if we have chosen an "aggressive" therapy and our mortality rate is lower, one third of patients have persistence/recurrence of cancer: it seems that tumour recurrence rate better reflects clinical problems related to cancer.

CONCLUSION: WDTC has with a good disease-specific survival but a significant recurrence rate. The most important predictors are the old age and the size of lesion. We suggest a radical surgery followed by radiometabolic ablation in all patients with WDTC.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app